Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the 4Kscore model, when adjusted for kallikrein marker changes due to finasteride use, improved the prediction of high-grade prostate cancer compared to adjusted total PSA alone in men taking 5-α-reductase inhibitors.

This study observed that although 5-alpha-reductase inhibitors reduce PSA density in patients on active surveillance for prostate cancer, those who progress to more serious disease still show higher PSA densities, suggesting these inhibitors accentuate differences in clinically significant cases.

This review discusses how 5α-reductase inhibitors affect PSA levels in benign prostatic hyperplasia treatment and their role in prostate cancer screening, but reports no new clinical findings.

Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.

This study found that dutasteride may reduce the likelihood of hospitalization for BPH-related surgery and newly detected prostate cancer, compared to finasteride, and suggests a budgetary benefit.

This study modeled how differences in trial settings and protocols, such as biopsy compliance and control arm screening, can explain the varying prostate cancer mortality reductions observed in the ERSPC and PLCO trials.

Finasteride significantly reduces prostate cancer risk.

Finasteride may help prevent prostate cancer, but more research is needed.

This study found that serum PSA levels and %fPSA have limited diagnostic capability in distinguishing prostate cancer, suggesting a need for new, more specific and sensitive markers.

5-ARI therapy may help prevent prostate cancer progression.

This article summarizes various studies in adult urology, including those on diagnostic techniques for prostate cancer and outcomes of different treatments for benign prostatic hyperplasia, but reports no new findings.

This study discusses two cases of acneiform skin eruptions associated with the use of the EGFR inhibitor ZD1839 in prostate cancer treatment, emphasizing the need for dermatologists to be aware of potential skin reactions.

Women in Australia report different signs of facial aging compared to women in the US, UK, and Canada; men with Lichen planopilaris often have hormonal abnormalities and thyroid disease.

This article discusses developments in clinical urology featured in the Journal of Urology's October 1999 issue and presents no new clinical findings.

In this case study, a male miniature dachshund with alopecia was diagnosed with estrogen-secreting Sertoli cell tumors and seminoma, with the alopecia resolving post-surgical removal of the tumor.

This study found that an earlier onset of androgenetic alopecia, especially in a frontal balding pattern, was significantly associated with an increased risk of prostate cancer among men at a Veterans Affairs Hospital.

In this study, 1 mg/day finasteride lowered serum PSA concentration in men aged 40–60, suggesting that PSA adjustment recommendations for prostate cancer screening using 5 mg/day finasteride should also apply to this lower dose for hair loss treatment.

This study found no difference in male pattern baldness between patients with benign prostate hyperplasia and prostate cancer, and no correlation with serum androgen levels.

This case-control study found that men with earlier onset androgenetic alopecia, particularly frontal balding, may have an increased risk of prostate cancer in a multiethnic veterans cohort.

CEC levels may be a useful marker for predicting prostate cancer progression.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

Gene variation affects prostate issues and hair loss.

This review discusses the potential benefits and risks of 5α-reductase inhibitors in preventing prostate cancer and reports no new results.

This review suggests that understanding the biological and molecular reasons for more severe COVID-19 in men, particularly those at risk for prostate cancer, could improve management of these patients, but reports no new results.

This article concludes that finasteride is a safe treatment for androgenetic alopecia and does not increase the risk of high-grade prostate cancer, despite past concerns from the Prostate Cancer Prevention Trial.

In this study, patients with larger prostates were observed to have a higher prevalence of androgenetic alopecia.

Finasteride is safe for hair loss treatment and doesn't increase high-grade prostate cancer risk.

This paper discusses prostate cancer diagnosis and treatment controversies and advocates for individualized approaches, reporting no new findings.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

No link found between hair loss severity and PSA levels in men.